Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1841 1
1846 1
1876 1
1878 1
1919 1
1929 1
1934 1
1945 1
1950 1
1951 2
1952 2
1953 1
1954 8
1955 3
1956 1
1957 2
1958 1
1959 2
1960 2
1961 1
1962 4
1963 9
1964 14
1965 9
1966 9
1967 9
1968 11
1969 8
1970 7
1971 12
1972 14
1973 20
1974 20
1975 23
1976 32
1977 25
1978 24
1979 30
1980 27
1981 29
1982 50
1983 61
1984 60
1985 53
1986 61
1987 95
1988 106
1989 105
1990 147
1991 157
1992 176
1993 186
1994 204
1995 213
1996 244
1997 244
1998 314
1999 651
2000 536
2001 576
2002 709
2003 710
2004 773
2005 855
2006 891
2007 1002
2008 1083
2009 1106
2010 1192
2011 1364
2012 1487
2013 1699
2014 2773
2015 3269
2016 3731
2017 4043
2018 5253
2019 7316
2020 9224
2021 10793
2022 10286
2023 12725
2024 15056
2025 18833
2026 4711

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112,458 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: ejoedono
Page 1
Showing results for R.D. ejoedono
Your search for R.D. Soejoedono retrieved no results
Innovation in the pharmaceutical industry: New estimates of R&D costs.
DiMasi JA, Grabowski HG, Hansen RW. DiMasi JA, et al. J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12. J Health Econ. 2016. PMID: 26928437
When compared to the results of the previous study in this series, total capitalized costs were shown to have increased at an annual rate of 8.5% above general price inflation. Adding an estimate of post-approval R&D costs increases the cost estimate to $2870 mi …
When compared to the results of the previous study in this series, total capitalized costs were shown to have increased at an annual rate of …
R&D productivity rides again?
Lendrem D, Senn SJ, Lendrem BC, Isaacs JD. Lendrem D, et al. Pharm Stat. 2015 Jan-Feb;14(1):1-3. doi: 10.1002/pst.1653. Epub 2014 Oct 22. Pharm Stat. 2015. PMID: 25336017 Review.
A recent analysis of R&D productivity suggests that there are grounds for 'cautious optimism' that the industry 'turned the corner' in 2008 and is 'on the comeback trail'. ...We present an alternative analysis of these same data to suggest that the industry is n …
A recent analysis of R&D productivity suggests that there are grounds for 'cautious optimism' that the industry 'turned th …
R&D re-balancing act.
Mullard A. Mullard A. Nat Rev Drug Discov. 2023 Apr;22(4):258. doi: 10.1038/d41573-023-00042-8. Nat Rev Drug Discov. 2023. PMID: 36890217 No abstract available.
Developing public-private R&D consortia to accelerate Alzheimer's disease drug development.
West J, Olk P. West J, et al. Drug Discov Today. 2024 Sep;29(9):104103. doi: 10.1016/j.drudis.2024.104103. Epub 2024 Jul 15. Drug Discov Today. 2024. PMID: 39019427 Free article. Review.
Efforts to accelerate Alzheimer's disease (AD) drug development have been spurred on by the creation of open science, public-private R&D consortia. An R&D consortium provides an improved structure for generating and disseminating AD knowledge a …
Efforts to accelerate Alzheimer's disease (AD) drug development have been spurred on by the creation of open science, public-private R …
R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
Schuhmacher A, Wilisch L, Kuss M, Kandelbauer A, Hinder M, Gassmann O. Schuhmacher A, et al. Drug Discov Today. 2021 Aug;26(8):1784-1789. doi: 10.1016/j.drudis.2021.05.005. Epub 2021 May 19. Drug Discov Today. 2021. PMID: 34022459 Review.
Comparative analysis of the R&D efficiency of 14 leading pharmaceutical companies for the years 1999-2018 shows that there is a close positive correlation between R&D spending and the two investigated R&D output parameters, ap …
Comparative analysis of the R&D efficiency of 14 leading pharmaceutical companies for the years 1999-2018 shows that there …
A FAIR-Decide framework for pharmaceutical R&D: FAIR data cost-benefit assessment.
Alharbi E, Skeva R, Juty N, Jay C, Goble C. Alharbi E, et al. Drug Discov Today. 2023 Apr;28(4):103510. doi: 10.1016/j.drudis.2023.103510. Epub 2023 Jan 27. Drug Discov Today. 2023. PMID: 36716952 Free article. Review.
Adherence to these principles in managing data assets in pharmaceutical research and development (R&D) offers pharmaceutical companies the potential to maximise the value of such assets, but the endeavour is costly and challenging. ...This framework supports dec …
Adherence to these principles in managing data assets in pharmaceutical research and development (R&D) offers pharmaceutic …
How much do the public sector and the private sector contribute to biopharmaceutical R&D?
Simoens S, Huys I. Simoens S, et al. Drug Discov Today. 2022 Apr;27(4):939-945. doi: 10.1016/j.drudis.2021.11.027. Epub 2021 Dec 1. Drug Discov Today. 2022. PMID: 34863932 Review.
When examining the prices of new medicines, the question of how much the private and public sectors have contributed to their R&D is often raised. Contributions can be assessed in terms of the investment, authorship of publications, marketing authorizations and …
When examining the prices of new medicines, the question of how much the private and public sectors have contributed to their R& …
Analysis of pharma R&D productivity - a new perspective needed.
Schuhmacher A, Hinder M, von Stegmann Und Stein A, Hartl D, Gassmann O. Schuhmacher A, et al. Drug Discov Today. 2023 Oct;28(10):103726. doi: 10.1016/j.drudis.2023.103726. Epub 2023 Jul 26. Drug Discov Today. 2023. PMID: 37506762
R&D productivity continues to be the industry's grand challenge. We analyzed the R&D input, output, and outcome of 16 leading research-based pharmaceutical companies over 20 years (2001-2020). Our analysis shows that pharma companies increased …
R&D productivity continues to be the industry's grand challenge. We analyzed the R&D input, output, and …
Effectiveness of R&D Tax Incentives in Turkey.
Taş E, Erdil E. Taş E, et al. J Knowl Econ. 2023 May 3:1-47. doi: 10.1007/s13132-023-01326-5. Online ahead of print. J Knowl Econ. 2023. PMID: 40479140 Free PMC article.
The questions of whether R&D tax incentives are effective in increasing business sector R&D intensity and to what extent R&D tax incentives produce additional R&D intensity are answered. According to the resu …
The questions of whether R&D tax incentives are effective in increasing business sector R&D intensity an …
112,458 results
You have reached the last available page of results. Please see the User Guide for more information.